13 news items
Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
AUTL
3 Jun 24
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
AUTL
31 May 24
patients with r/r ALL." The results of the FELIX trial have been submitted to the FDA as part of a BLA. The PDUFA target action
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
AKAN
AMPG
ASTS
17 May 24
the stock from Underperform to Buy and raised its price target from $14 to $24.
Losers
Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
AUTL
17 May 24
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
ASTS
AUTL
CDE
17 May 24
after B of A Securities upgraded the stock from Underperform to Buy and raised its price target from $14 to $24.
Mesoblast
l6dotvtwsxzp523hmc409gz
AUTL
17 May 24
review process for obecabtagene autoleucel (obe-cel) in adult ALL as we head towards the PDUFA target action date of November 16, 2024, and are driving
5d0u3xki11u4nem symg3h7fbx53il8m9w7dc7
AUTL
12 Apr 24
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
18r42i1av23cc lh6symhvrwokvxq70j08byvz2g58ifbbb5esxhgsrmpo
AUTL
9 Apr 24
Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $10 to $11.
jp8ocfaynpqqezf3f7dymur04xy23dgf7zbon9125hi
AUTL
2 Apr 24
with a Prescription Drug User Fee Act (PDUFA) target action date of November 16, 2024 LONDON, April 02, 2024 (GLOBE NEWSWIRE
r3oya4j3zil0i8n
AUTL
18 Mar 24
0
The 12-month price targets assessed by analysts reveal further insights, featuring an average
9w0u092cvqiuyzrycxj8838ojh8bu7rx0ncxvpz
AUTL
14 Mar 24
Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
p3atu0jvq35589c0r8jpgoejbqrvuoa1hn8qhvadk3i7gvq4a
AUTL
14 Mar 24
Act (PDUFA) target action date November 16, 2024Successfully completed first facility
3rdf7dtk116pddz8xtehvf uipdp4mibnxqg0pby4u
AUTL
12 Mar 24
cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed
- Prev
- 1
- Next